May 2, 2015 Dean N Silas Co-Medical Director Digestive ...€¦ · May 2, 2015 Dean N Silas...
Transcript of May 2, 2015 Dean N Silas Co-Medical Director Digestive ...€¦ · May 2, 2015 Dean N Silas...
May 2, 2015
Dean N Silas Co-Medical Director
Digestive Health Institute Advocate Lutheran General Hospital
Clinical Background
Treatment Approaches
PPI Side Effects
Acid Pocket
Endoscopic Therapy for GERD
Passage of gastric contents (gastroesophageal reflux) into esophagus is a normal physiologic process
GERD = Montreal definition “a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.”
NERD = Non Erosive Reflux Disease – no visible injury on EGD
Erosive Esophagitis – visible breaks in mucosa of distal esophagus
GERD patients do not hypersecrete acid
Acidic
Weakly acidic (non acid reflux)
Diminished gastric motility
Delayed esophageal clearance
Visceral hypersensitivity
TSLER
Acid Pocket
Common in Primary Care and GI Practice
Prevalence – 10-20% in Western populations
“Troublesome” heartburn in 6%
8.9 million OP visits
7.7 billion in annual US health care costs
Associated with BMI & waist circumference
Approx 25-42% do not respond to PPI including bid ppi
Katz et al. Guidelines for the Diagnosis and Management of GERD, Am J Gastroenterol 2013
Heterogeneous disorder
Typical symptoms – heartburn & regurgitation
Atypical sx – dyspepsia, bloating, belching, epigastric pain, nausea
Other causes are more likely
Extraesophageal sx – laryngitis, cough, asthma
Significant effects on QOL
Sleep disturbances!
Initial studies from tertiary referral centers suggested annual progression to EAC as high as 2.4%
Recent population based studies report much lower risk
Netherlands 0.4%
Ireland 0.27%
Denmark 0.12%
US Veterans 0.32%
Shakhatreh MH et al. Am J Gastroenterol, 2014
Controversial
Particularly considering low incidence of EAC
Consider in males > 50 with
Long standing symptoms (> 5 yrs?)
Smokers
Elevated BMI
Intra-abdominal fat distribution
Katz et al. Guidelines for the Diagnosis and Management of GERD, Am J Gastroenterol 2013
EGD not required in presence of typical sx
Specific finding (erosive esophagitis, Barrett’s, stricture) present in minority
Cardiac chest pain should be excluded
EGD for
“Alarm symptoms” dysphagia, bleeding, wt loss, chest pain require EGD
If diagnosis is uncertain
Distal esophageal biopsy not required
Effect of evaluation for EoE
Katz et al. Guidelines for the Diagnosis and Management of GERD, Am J Gastroenterol 2013
Optimal treatment is controversial Mainstay of treatment is pharmacologic
Step Up Therapy Start with low dose H2RA and increase
For treatment naïve patients with mild, infrequent (<2x/wk) sx
Potential lower costs, delayed response
Step Down Therapy Start with daily PPI
Consider trial of drug withdrawal Not in LA Class C, D or Barrett’s
PPI’s Work Here
Digestion of protein
Absorption of iron, calcium, and vitamin B12
Prevents bacterial overgrowth in small intestine, enteric infections, and possibly community acquired pneumonia
Early studies of medical treatment of endoscopic healing of erosive esophagitis
PPI 84% H2RA 52% Sucralfate 39% Placebo 28%
Recommended initial course of treatment
8 week trial of once daily PPI
30 minutes before first meal of day
No significant differences between PPI’s
Tailor dose to response
Adjust timing
Consider BID dosing if partial response
Consider nighttime H2RA for nocturnal sx
No significant differences in efficacy between PPI’s
Small (relevance uncertain – NNT- 25) improved healing and symptom relief with esomeprazole (Omep – NaHCO3 & dexlansoprazole not included in metanalysis)
All PPI’s are delayed release EXCEPT
Omeprazole-NaHCO3 – immediate release
Possible role for nocturnal dosing?
Dexlansoprazole – dual delayed release
Remarkably well tolerated Headache, diarrhea most common
Recent interest in long term complications C difficile
Large Metaanalyses show OR ~1.6-2
Multiple possible confounders in analysis
Be aware of the possible association with c. diff, (but not recurrent c. diff?)
Consider stopping PPI in pts with documented c. diff
Caution with PPI in hospitalized pts on antibiotics
Community Acquired Pneumonia
Risk is greatest in first few days of rx, particularly high dose
Johnson DA & Oldfield EC. Clin Gastroenterol Hepatol 2013
Bone Fracture
Gastric acid contributes to calcium absorption, but clinical effect of PPI on calcium absorption is minimal
FDA product label warning 2010
But, data is conflicting and studies are poor
If there is a risk for fracture, it is low
No need to stop PPI for appropriate indications in appropriate doses
No need for calcium supplements
Hypomagnesemia Rare, < 50 case reports Mechanism unknown – not renal or GI wasting No typical patient profile FDA Alert (2011)
“Healthcare professionals should consider obtaining serum magnesium levels prior to initiation of prescription PPI treatment in patients expected to be on these drugs for long periods of time, as well as patients who take PPIs with medications such as digoxin, diuretics or drugs that may cause hypomagnesemia”
FDA alert seems impractical
Vitamin B12 Deficiency Acid involved in releasing B12 from protein Inconsistent data regarding clinical relevance PPI should have no impact on absorption of medicinal B12
Infections in cirrhotics
Increased risk of SBP and increased mortality in decompensated cirrhotics
Consider stop PPI, or switch to H2RA
Microscopic colitis
Interstitial nephritis
Sucralfate No role except pregnant women
Baclofen Reduces frequency of TSLER (transient spontaneous lower
esophageal relaxation), reflux episodes, nocturnal reflux, and belching
5-20 mg tid Side effects – somnolence, dizziness, constipation
Prokinetic agents Metoclopramide
Improves LES Pressure, esophageal clearance, gastric emptying No large clinical studies Significant side effects
Alginic acid Discussed later
Post prandial reflux is hallmark symptom of GERD
Intragastric acidity varies in different areas of the stomach
pH studies demonstrate that pH of refluxate is more acidic than the gastric body
The “acid pocket” concept was proposed in 2001 Zone of highly acidic gastric juice
Extends for 2-3 cm below GEJ
Not buffered by stomach contents
Thought to be due to gastric acid layering on the meal Poor contractility of the proximal stomach
Mixing occurs in gastric antrum
Pre Meal 3 min pc
17 min pc Acid pocket 43 min pc
Reflux episode 73 min pc
Kahrilas et al. Am J Gastroenterol, 2013
Importance of postural recommendations
Alginates (Gaviscon) Natural polysaccharide polymers – Norwegian seaweed
Precipitate on contact with acid forming neutral pH low density (floating) gel
NaHCO3 -> CO2 trapped in viscous gel forming a “raft” and “capping” the acid pocket
Recent studies document that alginate Co-localized with Acid Pocket
Displaced acid pocket away from GEJ
Decreased reflux episodes
Delayed time to first reflux
Higher pH of refluxate Kwiatek MA, et al. Aliment Pharmacol Ther 2011 Rohof WO et al. Clin Gastroenterol Hepatol 2013
Acid pocket is larger and extends further into esophagus in GERD patients Pocket frequently located in
supradiaphragmatic location in pts with HH
Increases likelihood of reflux
Concept of acid film coating mucosa in LES Long contact time with GEJ
mucosa causing contributing to esophagitis and Barrett’s?
Mild heartburn/reflux without alarm symptoms
Heartburn in pregnant women
On demand therapy for pts with post prandial symptoms
Add on therapy with PPI? Different mechanism of action than PPI
No effect on gastric acid secretion
Limited data
Rationale
Symptom relief
Stop medications
Normalize acid exposure to esophagus
Avoid risks/complications/costs of surgical rx
Gas/bloat
Dysphagia
Diarrhea
Radiofrequency Ablation (Stretta)
Initially released early 2000’s
Re-introduced to market 2010
Lipka et al. Clin Gastroenterol Hepatol 2014
LES pressure HCQOL
pH < 4 Stop PPI
No improvement in objective parameters or QOL Not Recommended
Hunter JG et al. Gastroenterol 2015
Multicenter - TIF/placebo vs Sham/PPI
Barrett’s < 2 cm
Hiatal hernia < 2 cm
No LA Grade C or D esophagitis
Primary Endpoint – relief of regurgitation
TIF – 67% Sham/PPI – 45%
Reduced reflux episodes / 6 months
pH improved, not normalized
PPI does not normalize reflux
Hunter JG et al. Gastroenterol 2015
Short term improvement in regurgitation
Long term results not available
If extrapolate from Nissen data, then sx may recur over time
No direct comparison to other endoscopic therapies or surgical therapy
Option available for motivated highly selected patients
Titanium beads with magnetic core connected with titanium wire to form “bracelet”
Magnetic beads keep LES closed
Swallowing force overcomes magnetic force
Placed with minimally invasive surgery
FDA approved 3/2012
Minor side effects in small studies
Dysphagia, odynophagia, chest pain, nausea, vomiting
Pt can NOT undergo MRI
Role not clarified
GERD is an extremely common GI disorder
Heterogeneous pathophysiology
Acid & non acid reflux
Role of Acid Pocket
PPI’s remain mainstay of treatment
Long term use of PPI controls symptoms in most
Recent publicity re: PPI side effects are overstated
Endoscopic therapies available
Role is not clarified
Consider in only highly selected patients